First TRP-8803 BED patient shows broad clinical improvement
Filed with ASX · · 6 pages · English
• First patient treated with TRP-8803 (IV-psilocin) in ENP’s Binge Eating Disorder (BED) trial has successfully completed the 4-week post-treatment assessment • Clinically meaningful improvements achieved across a wide range of BED-related symptoms following two TRP-8803 infusions • Clinically significant improvements observed in binge eating severity, depression, anxiety, body image satisfaction
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- TRP-8802 Phase 2a Trial Shows Sustained BED Reduction
- $847,186 R&D Tax Incentive received
- First BED patient completes second TRP-8803 infusion
- First patient successfully dosed in TRP 8803 BED trial
- BED trial accelerates - enrolment grows, dosing in two weeks
Later from Entropy Neurodynamics
- Quarterly Activities Report and Appendix 4C
- Australian Patent Secures TRP 8803 Platform to 2042
- Appendix 4D and Half Year Report for period 31 Dec 2025
- Cohort 1 enrolment achieved for TRP-8803 BED Trial
- FY25 R&D Tax Incentive received
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics